Lung Cancer Trials Ask AI to find trials
CompletedPhase 3NCT00086268
Official study title

Non-small Cell Lung Cancer Study US75 (Z-PACT)

Study summary

This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.

Ask AI to explain this study
Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedzoledronic acid and Taxotere

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 13, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?80 U.S. locations

Locations may change over time.

Who runs it?Novartis Pharmaceuticals

Study sponsor

01
Study overview

What this study is about

Purpose
Prevention
Study type
Interventional
Phase
Phase 3
Sponsor
Novartis Pharmaceuticals
Interventions being studied
Drug: zoledronic acid; Drug: Taxotere; Drug: Carboplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Male or Female patients at least of 18 years old
  • Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery
  • Women must not be pregnant or attempting to become pregnant
  • Able and willing to sign informed consent
Reasons someone may not be able to joinExclusion criteria
  • Patients with cancer that has spread to the bone
  • Patients with cancer that has spread to the brain who are receiving treatment
  • Patients with kidney disease
  • Patients treated with other investigational drugs

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Clinical Research ConsultantsHoover, Alabama
  • Arizona Oncology Assoc.Tucson, Arizona
  • NEA ClinicJonesboro, Arkansas
  • Highlands Oncology GroupSpringdale, Arkansas
  • NorthBay Cancer CenterFairfield, California
  • UCLALos Angeles, California
  • Clinical Trials and Research Associates, Inc.Montebello, California
  • Med. Oncology Care AssociatesOrange, California
  • Cancer Center of Santa BarbaraSanta Barbara, California
  • Cancer Center of Colorado SpringsColorado Springs, Colorado
  • Northern Hematology-OncologyThornton, Colorado
  • Lynn Regional Cancer CenterBoca Raton, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 13, 2017. Always confirm current availability with the study team.

View original record ↗